Armstrong Anne C, Dermime Said, Mulryan Kate, Stern Peter L, Bhattacharyya Tapan, Hawkins Robert E
Cancer Research UK Department of Medical Oncology, Paterson Institute of Cancer Research, Christie Hospital NHS Trust, Manchester, UK.
J Immunother. 2004 May-Jun;27(3):227-31. doi: 10.1097/00002371-200405000-00007.
There is extensive interest in idiotypic vaccination as a treatment of lymphoma. An alternative approach is the adoptive transfer of in vitro generated T cells. This strategy has been used to treat posttransplantation EBV-related diseases. The ability to generate in vitro T cells to peptides derived from immunoglobulin idiotypes raises the possibility of directly using such cells as a treatment of lymphoma. Investigating the adoptive transfer of specific T cells to idiotype derived peptides in a murine lymphoma model is therefore an important part of the clinical translation of this alternative approach. We have generated an idiotype-specific T cell line, able to recognise a defined, naturally processed idiotype-derived epitope. This line has been used to successfully treat mice with disseminated lymphoma supporting the clinical use of idiotype specific T cells.
作为淋巴瘤的一种治疗方法,独特型疫苗接种引起了广泛关注。另一种方法是过继转移体外产生的T细胞。这种策略已被用于治疗移植后与EB病毒相关的疾病。体外产生针对源自免疫球蛋白独特型的肽段的T细胞的能力,增加了直接使用此类细胞治疗淋巴瘤的可能性。因此,在小鼠淋巴瘤模型中研究将特异性T细胞过继转移至源自独特型的肽段,是这种替代方法临床转化的重要组成部分。我们已经建立了一种独特型特异性T细胞系,它能够识别一个明确的、自然加工产生的源自独特型的表位。该细胞系已成功用于治疗患有播散性淋巴瘤的小鼠,支持独特型特异性T细胞的临床应用。